


Daily Journal

MAY 20, 2026

TOP INTELLECTUAL PROPERTY LAWYERS 2026



HONORING TOP ATTORNEYS WORKING IN PATENT, TRADEMARK AND COPYRIGHT LAW



SIEGMUND GUTMAN

MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.

LOS ANGELES

Siegmund Gutman's path into patent law began not in a courtroom, but in a laboratory. As a graduate student at UC Berkeley in the early 1990s, he worked on automated DNA sequencing technologies as part of the Human Genome Project — a project he describes as "almost like the life sciences equivalent of the Manhattan Project." The work involved universities, federal agencies, and private sponsors, and the questions it raised about invention and ownership never left him.

"That curiosity about the intersection of science, innovation, and legal rights stayed with me and ultimately drew me toward patent law," Gutman said.

Gutman had intended to pursue academia, but the economic climate of the early 1990s redirected him toward law school. He began his legal practice in 1997 and has spent nearly three decades litigating patent disputes, with a focus on life sciences. He is now chair of Mintz's life sciences litigation practice and co-chair of its patent litigation and life sciences practices.

An early career-defining matter was *Ariad Pharmaceuticals v. Amgen*, a case that stretched nearly two decades. At issue was a patent Ariad asserted covered Amgen's blockbuster drug Enbrel, with the underlying technology centering on a transcription factor called NF- κ B and the intricacies of intracellular signaling biology. "The cast of characters included Nobel Prize-winning scientists and many of the most prominent research laboratories in the world," Gutman said. Amgen prevailed on the infringement question.

His recent matters reflect the same intersection of legal, scientific, regulatory and commercial complexity. In coordinated BPCIA litigation over Amgen's Prolia and XGEVA biologics, Gutman has managed strategy across multiple biosimilar developers and jurisdictions, with parallel proceedings in Europe and Asia. The work has included settlements with Celltrion and Fresenius Kabi, and a Section 1782 discovery dispute that reached the Third Circuit.

"The matters are significant because they involve globally important biologics portfolios with multibillion-dollar implications," Gutman said.

In separate proceedings before the PTAB and Federal Circuit, Gutman served as lead counsel for Sanofi Pasteur and SK bioscience in a challenge to a Pfizer patent covering pneumococcal conjugate vaccines. He obtained PTAB decisions invalidating all original claims, successfully defended those results on appeal, and secured a precedential Federal Circuit opinion. On remand, the PTAB also rejected Pfizer's proposed amended claims. Pfizer has appealed again, and the matter continues. The case, Gutman says, "removed a major patent barrier to competitive vaccine development and clarified important legal issues in the patentability of multivalent immunogenic compositions."

Across both matters, Gutman sees a common theme: the need to keep litigation strategy aligned with business objectives in markets where timing and regulatory considerations shape outcomes. He identifies "the dynamic nature of patent law as it relates to life sciences issues and the interplay between parallel proceedings, for example, the interplay between the initiation of post-grant proceedings at the USPTO and the pendency of proceedings in district court and even the International Trade Commission" as among the most pressing challenges for practitioners in the field today.